Evidence map›Paper›PMID 29209043›Full record

ArticleLeukemia2018

CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.

I Tirado-Gonzalez, E Czlonka, A Nevmerzhitskaya, D Soetopo, E Bergonzani, A Mahmoud, A Contreras, I Jeremias, U Platzbecker, J P Bourquin and 3 more

Erratum issuedAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

I Tirado-GonzalezGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
E CzlonkaGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
A NevmerzhitskayaGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
D SoetopoGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
E BergonzaniGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
A MahmoudGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
A ContrerasGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
I JeremiasDepartment of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Münich, German Center for Environmental Health (HMGU), Munich, Germany.
U PlatzbeckerUniversity Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
J P BourquinDivision of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland.
U KlozDivision of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland.
F Van der HoevenTransgenic Service, German Cancer Research Center, Heidelberg, Germany.
H MedyoufGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.

Funding

European Research Council 639795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsDisease ProgressionGene EditingHematologic NeoplasmsHeterograftsHumansLeukemiaMiceMice, Inbred C57BLMice, Inbred NODOsteonectinTumor MicroenvironmentOsteonectin

Identifiers

PMID29209043
PMCPMC7703605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.